Stock Monitor: Urogen Pharma Post Earnings Reporting

LONDON, UK / ACCESSWIRE / November 27, 2017 / Active-Investors issued a free report on Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) ("Portola"), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=PTLA as the Company's latest news hit the wire. On November 21, 2017, the biopharmaceutical Company, which develops product candidates in the fields of thrombosis and other hematologic diseases, announced that the US Food and Drug Administration ("FDA", or 'the agency') has extended the review period for its Prior Approval Supplement (PAS) for Bevyxxa® (betrixaban). This would give sufficient time to the agency to thoroughly review Portola's submission. Sign up now for our free research reports at: www.active-investors.com/registration-sg.

Active-Investors.com is currently working on the research report for Urogen Pharma Ltd (NASDAQ: URGN), which also belongs to the Healthcare sector as the Company Portola Pharma. Do not miss out and become a member today for free to access this upcoming report at: www.active-investors.com/registration-sg/?symbol=URGN.

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Portola Pharma most recent news is on our radar and we have decided to include it on our blog post. Today's free coverage is available at: www.active-investors.com/registration-sg/?symbol=PTLA.

About Bevyxxa®

  • Bevyxxa® is Portola's first medicine. It is an oral, once-daily Factor Xa inhibitor, which was approved by the FDA on June 23, 2017.
  • Currently, Bevyxxa® is the first and only anticoagulant for hospital and extended duration prophylaxis (i.e. around 35 to 42 days) of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness, and who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE.

Notification from the FDA

  • The FDA communicated to Portola that it would revert on its PAS request to change the existing manufacturing release specification within the standard extension period of 60 days.
  • The agency specified a new action date of January 30, 2018.
  • However, the FDA did not ask for any additional information from Portola at this point.

Bevyxxa® Commercial Launch Expected in February 2018

Bill Lis, Chief Executive Officer (CEO) at Portola, shared that the Company has made good progress with the FDA for the product release so far. Portola has already entered into an agreement in principle for the change of its product release specification, which would help in the release and distribution of the existing product inventory.

The FDA might need more time to review the PAS application. And while the agency completes its review, the momentum for Bevyxxa® within the medical community is building. Portola expects to commercially launch Bevyxxa® by February 2018. Till then, it intends to continue with its commercial and medical education activities, in preparation for the launch.

Once Bevyxxa® launches, it would prove to be a potentially life-saving new therapy for VTE in hospitalized adult patients who at risk of developing VTE.

Portola Shared Third Quarter 2017 Results

Portola reported its financial results on November 06, 2017, for the third quarter ending September 30, 2017.

  • The total collaboration and license revenue earned by the Company was $3.8 million, down from $9.3 million for the third quarter of 2016.
  • Portola reported a net loss of $82.9 million, or $1.41 net loss per share, compared to a net loss of $92.9 million, or $1.64 net loss per share, for the same period in 2016.
  • The net cash, cash equivalents, and investments totaled $597.8 million.

Stock Performance Snapshot

November 24, 2017 - At Friday's closing bell, Portola Pharma's stock fell 1.40%, ending the trading session at $50.55.

Volume traded for the day: 330.61 thousand shares.

Stock performance in the last month ? up 3.50%; previous six-month period ? up 37.66%; past twelve-month period ? up 167.04%; and year-to-date ? up 125.27%

After last Friday's close, Portola Pharma's market cap was at $3.35 billion.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.3% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors